{
  "docId": "019de070-c9e1-7644-aac7-afa340d8795d",
  "docSlug": "fc9db8b68eed863ebdeb09cbc0c7e18a",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 86 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 53,
  "pageCount": 86,
  "prevPage": 52,
  "nextPage": 54,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "Includes footnotes for clinical trial abbreviations and data sources.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c9e1-7644-aac7-afa340d8795d/53",
  "deckHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d",
  "deckJsonHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d.json",
  "deckAnchorHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d#slide-53",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.68,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Next milestone: US FDA Cardiovascular and Renal Drugs Advisory Committee",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a9163bb-c445-448f-a260-6ce57328e345",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.35,
        "y": 0.6
      },
      "kind": "chart",
      "text": "RBC transfusion incidence rate per 100 patient-years at risk for OLYMPUS, ALPS, ANDES trials",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40628145-553b-469b-a292-d1836afe3a40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.28,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "chart",
      "text": "China revenue growth by quarter in 2020",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "988fbb3a-469f-423c-9a25-86438703e5fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "1. Collaboration with FibroGen... 11. Erythropoietin stimulating agents. Source: Abstract TH-OR05, ASN 2020.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28b433c3-6b3c-4e41-8c70-851177b74b22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "list",
      "text": "MACE/CV event rates lowest at Hb >=10 g/dL; Reduced risk of hospitalisation for HF vs. ESA; Not associated with increased risk of neoplasm",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c2e92ce-3e0e-45bb-82e6-231f65264cf7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "list",
      "text": "Leverages the body’s natural response to hypoxia; Consistent Hb control; Reduction in RBC transfusion risk; Effect independent of inflammation; Reduces potential need for IV iron; Pooled analysis demonstrated CV safety; Convenient oral administration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bee23cab-8914-4f4d-b235-d65239e65f48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Roxadustat: Shifting the treatment paradigm for patients with anaemia from CKD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfddd8b4-b2f3-4597-8af4-d13206d3276b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "3058853e-a10a-4ed5-aa21-422626d461a5",
      "evidence": "The slide includes a bar chart (RBC transfusion incidence rate) and a vertical bar chart (China revenue growth), indicating a selection of charts to present data.",
      "confidence": 0.7
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "bff2f808-2ed2-43e5-815b-23ebeb831661",
      "evidence": "The slide contains a list of bullet points describing the features of Roxadustat.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}